Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 14/20 | 0.67 |
| ▸ | NPC1 | O15118 | 13/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.61 |
| ▸ | HPGD | P15428 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7980934 | 0.79 | RAB9A (0.64) | RAB9ANPC1POLBSMN1; SMN2HPGD | |
| SCHEMBL3455511 | 0.76 | RAB9A (0.81) | RAB9ANPC1POLBSMN1; SMN2HPGD | |
| SCHEMBL7996705 | 0.75 | L3MBTL1 (1.00) | RAB9ANPC1POLBSMN1; SMN2HPGD | |
| SCHEMBL9980492 | 0.74 | L3MBTL1 (0.98) | RAB9ANPC1POLBSMN1; SMN2HPGD | |
| SCHEMBL7990085 | 0.73 | RAB9A (0.77) | RAB9ANPC1POLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL16157058 | 0.73 | NPC1 (0.61) | RAB9ANPC1POLBSMN1; SMN2HPGD | |
| SCHEMBL12660702 | 0.72 | RAB9A (0.79) | RAB9ANPC1POLBSMN1; SMN2HPGD | |
| SCHEMBL16383897 | 0.72 | RAB9A (0.77) | RAB9ANPC1POLBSMN1; SMN2HPGD | |
| SCHEMBL7983639 | 0.71 | NPC1 (1.00) | RAB9ANPC1POLBSMN1; SMN2HPGD | |
| SCHEMBL19995125 | 0.69 | KMT2A (0.98) | RAB9ANPC1POLBSMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096585-B2 | Antiviral compounds and uses thereof | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096585-B2 | Antiviral compounds and uses thereof | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096585-B2 | Antiviral compounds and uses thereof | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2015-08-04 | — | — | US | disclosed |
| US-8629283-B2 | Compounds that modulate negative-sense, single-stranded RNA virus replication and uses thereof | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2014-01-14 | — | — | US | disclosed |
| US-8629283-B2 | Compounds that modulate negative-sense, single-stranded RNA virus replication and uses thereof | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2014-01-14 | — | — | US | disclosed |
| US-20130137678-A1 | Antiviral Compounds and Uses Thereof | MOUNT SINAI SCHOOL OF MEDICINE (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130137678-A1 | Antiviral Compounds and Uses Thereof | MOUNT SINAI SCHOOL OF MEDICINE (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130137678-A1 | Antiviral Compounds and Uses Thereof | MOUNT SINAI SCHOOL OF MEDICINE (US) | 2013-05-30 | — | — | US | disclosed |
| WO-2011150413-A1 | ANTIVIRAL COMPOUNDS AND USES THEREOF | MOUNT SINAI SCHOOL OF MEDICINE (US) | 2011-12-01 | — | — | WO | disclosed |
| US-20110105423-A1 | COMPOUNDS THAT MODULATE NEGATIVE-SENSE, SINGLE-STRANDED RNA VIRUS REPLICATION AND USES THEREOF | MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY (US) | 2011-05-05 | — | — | US | disclosed |
| US-20110105423-A1 | COMPOUNDS THAT MODULATE NEGATIVE-SENSE, SINGLE-STRANDED RNA VIRUS REPLICATION AND USES THEREOF | MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY (US) | 2011-05-05 | — | — | US | disclosed |
| WO-2009136979-A2 | COMPOUNDS THAT MODULATE NEGATIVE-SENSE, SINGLE-STRANDED RNA VIRUS REPLICATION AND USES THEREOF | MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137678-A1 | Antiviral Compounds and Uses Thereof | MAVS, ZC3HAV1, EIF2AK2 | RAB9A 1922/4885NPC1 649/4885POLB 169/4885 |
| US-20110105423-A1 | COMPOUNDS THAT MODULATE NEGATIVE-SENSE, SINGLE-STRANDED RNA VIRUS REPLICATION AND USES THEREOF | EIF2AK2, NSUN2, ADAR | RAB9A 3430/4885NPC1 3196/4885POLB 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.